Pfizer Inc. (NYSE:PFE) Shares Sold by Acorn Financial Advisory Services Inc. ADV

Acorn Financial Advisory Services Inc. ADV trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 6,996 shares of the biopharmaceutical company’s stock after selling 603 shares during the quarter. Acorn Financial Advisory Services Inc. ADV’s holdings in Pfizer were worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $315,000. GSA Capital Partners LLP purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $439,000. Duality Advisers LP purchased a new stake in Pfizer in the 1st quarter worth $1,009,000. Clifford Capital Partners LLC increased its holdings in Pfizer by 29.3% in the 1st quarter. Clifford Capital Partners LLC now owns 442,593 shares of the biopharmaceutical company’s stock worth $12,282,000 after acquiring an additional 100,210 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Pfizer in the 1st quarter worth $40,712,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of several recent research reports. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Performance

NYSE:PFE traded down $0.32 during midday trading on Friday, reaching $26.72. The stock had a trading volume of 55,951,315 shares, compared to its average volume of 37,583,031. The firm has a fifty day simple moving average of $28.89 and a two-hundred day simple moving average of $28.63. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a quick ratio of 0.60, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $151.42 billion, a P/E ratio of 36.12, a P/E/G ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the firm posted ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.29%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.